ストックスクリーナーアプリを入手
7.0777
2.41%
-0.1723
Replimune Group Inc (REPL) 最新ニュース
Replimune Stock Quote, Share Price, News and Analysis - Longbridge
REPL Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Does Replimune Group (REPL) Possess the Opportunity to Surge by 79.61% According to Wall Street Analysts' Predictions? - Bitget
Does Replimune Group (REPL) Have the Potential to Rally 79.61% as Wall Street Analysts Expect? - Finviz
Replimune to Present at Two Upcoming Investor Conferences - marketscreener.com
Replimune at Leerink, Jefferies investor events March 9–10 - Stock Titan
Replimune Group, Inc. (NASDAQ:REPL) Given Average Rating of "Hold" by Analysts - MarketBeat
Erste Asset Management GmbH Increases Stock Position in Replimune Group, Inc. $REPL - MarketBeat
Replimune Group, Inc. (REPL) Stock Analysis: A High-Potential Biotech Play with 67% Upside - DirectorsTalk Interviews
Replimune Group Stock Price Forecast. Should You Buy REPL? - StockInvest.us
Replimune's Pivotal FDA Verdict Approaches - AD HOC NEWS
Market Leaders: Can Replimune Group Inc expand its profit margins2025 Fundamental Recap & Reliable Breakout Forecasts - baoquankhu1.vn
Analyst Calls: Is Apyx Medical Corporation in accumulation or distribution phaseEarnings Miss & Real-Time Volume Analysis - baoquankhu1.vn
Replimune Shares Approach a Pivotal Regulatory Milestone - AD HOC NEWS
Replimune Group, Inc. (REPL) Stock Analysis: Unpacking a 50% Potential Upside in Biotechnology - DirectorsTalk Interviews
Replimune: Multiple Shots On Goal But A High Risk Binary Approaches - Seeking Alpha
What is Replimune Group Inc.’s market positionQuarterly Profit Summary & Precise Swing Trade Entry Alerts - mfd.ru
Replimune Group (REPL) director gifts 25,000 common shares - Stock Titan
Institutional Confidence Surges in Replimune as Key Drug Review Looms - AD HOC NEWS
Replimune Group (NASDAQ:REPL) Trading Up 13.3%Here's Why - MarketBeat
Replimune rebounds despite analyst downgrades on FDA rejection - MSN
Replimune Group (NASDAQ:REPL) Stock Price Down 7.8%Here's What Happened - MarketBeat
Wall Street analysts predict a 65.72% upside in Replimune Group (REPL): Here's what you should know - MSN
How Replimune Group Inc. stock reacts to job market dataWeekly Trade Analysis & Risk Controlled Stock Pick Alerts - mfd.ru
Will Replimune Group Inc. stock outperform tech sector in 20252025 Fundamental Recap & Low Risk Entry Point Guides - mfd.ru
Can Replimune Group Inc. be recession proofJuly 2025 Big Picture & High Conviction Investment Ideas - mfd.ru
Wall Street Analysts Predict a 65.72% Upside in Replimune Group (REPL): Here's What You Should Know - Finviz
Buybacks Report: Can Replimune Group Inc expand its profit marginsMarket Performance Recap & Low Drawdown Momentum Trade Ideas - baoquankhu1.vn
Replimune Group, Inc. (REPL) stock news today: Live updates - Bitget
Is now the right time to enter Replimune Group Inc.Analyst Downgrade & Verified Entry Point Signals - mfd.ru
Insider Sell: Is Replimune Group Inc stock undervalued right now2025 Market Outlook & Daily Growth Stock Investment Tips - baoquankhu1.vn
Why Replimune Group Inc. stock is favored by pension fundsJuly 2025 Momentum & Entry Point Confirmation Signals - mfd.ru
Is Replimune Group (NASDAQ:REPL) A Risky Investment? - simplywall.st
Replimune Group (NASDAQ:REPL) Price Target Raised to $14.00 - MarketBeat
Piper Sandler Maintains 'Overweight' Rating for REPL, Raises PT to $14 | REPL Stock News - GuruFocus
Johnson Fistel, PLLP Begins Investigation on Behalf of - GlobeNewswire
Replimune Secures Financial Runway Through 2027 - AD HOC NEWS
Analysts Are Neutral on Top Healthcare Stocks: Replimune Group (REPL), ACADIA Pharmaceuticals (ACAD) - The Globe and Mail
Replimune Group, Inc. (NASDAQ:REPL) Receives Average Rating of "Hold" from Brokerages - MarketBeat
Wedbush Issues Positive Forecast for Replimune Group (NASDAQ:REPL) Stock Price - MarketBeat
Replimune Group (REPL) to Release Quarterly Earnings on Wednesday - MarketBeat
Here's Why Replimune Stock Skyrockets Nearly 131% in 3 Months - MSN
Replimune (REPL) Awaits FDA Approval for RP1 in Melanoma Treatme - GuruFocus
Replimune Group Q3 Earnings Summary & Key Takeaways - Benzinga
Replimune amends Hercules loan, strengthens funding runway - TipRanks
Earnings Summary: Replimune Group Q3 - Benzinga
Replimune Group, Inc. SEC 10-Q Report - TradingView
RP1 melanoma setback and SEC probe weigh on Replimune (NASDAQ: REPL) - Stock Titan
Earnings Breakdown: Replimune Group Q3 - Benzinga
Replimune Group Signs Loan and Security Agreement Amendment With Hercules Capital - TradingView
Replimune Reports Fiscal Third Quarter 2026 Financial Results and Provides Corporate Update - The Manila Times
Replimune Group, Inc. Enters into Third Amendment to Loan and Security Agreement with Hercules Capital, Inc - marketscreener.com
Replimune Group, Inc. (REPL): Investor Outlook Reveals 70% Potential Upside In Innovative Cancer Therapies - DirectorsTalk Interviews
Oncolytic Virotherapy Market - GlobeNewswire Inc.
Replimune Group, Inc. (REPL) Stock Analysis: A 59% Potential Upside In Oncolytic Immunotherapy - DirectorsTalk Interviews
Replimune Group (NASDAQ:REPL) Sees Large Volume IncreaseTime to Buy? - MarketBeat
Johnson Fistel, PLLP Investigates Claims on Behalf of - GlobeNewswire
Aug Analyst Calls: Is now the right time to enter Replimune Group IncQuarterly Profit Summary & Free Technical Pattern Based Buy Signals - baoquankhu1.vn
Replimune Group (NASDAQ:REPL) Trading Down 5.4%Should You Sell? - MarketBeat
4.12%
大文字化:
|
ボリューム (24 時間):